H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Spectral AI today and set a price target of $3.50.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Swayampakula Ramakanth’s rating is based on several key factors that highlight the potential of Spectral AI’s DeepView system. The company has recently completed its FDA submission for the DeepView system, which is anticipated to be a major turning point once approved. The involvement of BARDA in the pre-submission meetings and their commitment to assist with initial device purchases upon approval further strengthens the prospects of a successful launch.
Financially, Spectral AI reported revenues of $5.1M for 2Q25, although slightly below consensus estimates, the company maintains a strong cash position to support operations into 2Q26. The analyst’s valuation, which includes a net present value analysis of future revenues from DeepView AI, supports a 12-month price target of $3.50 per share. Despite potential risks such as regulatory and competitive challenges, the combination of strategic developments and financial projections justifies the Buy rating.
According to TipRanks, Ramakanth is a 4-star analyst with an average return of 7.3% and a 38.00% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Precigen, and Eton Pharmaceuticals.
In another report released yesterday, Northland Securities also maintained a Buy rating on the stock with a $6.00 price target.